SCOPUS 정보 검색 플랫폼

Anticancer Research

Volumn 20, Issue 6 D, 2000, Pages 4985-4987

Prostate specific antigen in as a dynamic model in advanced prostate cancer

(6) Schmid, H P a Bernhard, J a Semjonow, A a Hanselmann, S a Hertle, L a Maibach, R a

a UNIVERSITY OF MÜNSTER (Germany)

Author keywords

Chemotherapy; Hormone resistance; Prostate specific antigen doubling time; Prostatic neoplasms

Indexed keywords

GONADORELIN AGONIST; IDARUBICIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESISTANCE; HUMAN; MALE; MODEL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; DRUG RESISTANCE, NEOPLASM; HORMONES; HUMANS; IDARUBICIN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0034452067 PISSN: 02507005 EISSN: None Source Type: Journal
DOI: None Document Type: Conference Paper

Times cited : (1)

References (10)

1
- 0002811281
- Treatment of hormone resistant disease
- (WHO-UICC) (Murphy G, Griffiths K, Denis L, Khoury S, Chatelain C, Cockett AT, eds). Scientific Communication International Ldt.
- (1997) Proceedings of the first international consultation on prostate cancer , pp. 325-342
- Rübben, H.¹ Dijkman, G.² Ferrari, P.³ Fournier, G.⁴ Hirao, Y.⁵ Kirk, D.⁶

2
- 0031726901
- Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials
- (1998) J Clin Oncol , vol.16 , pp. 3398-3405
- Dawson, N.A.¹

3
- 0032747375
- Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
- (1999) J Clin Oncol , vol.17 , pp. 3461-3467
- Bubley, G.J.¹ Carducci, M.² Dahut, W.³ Dawson, N.⁴ Daliani, D.⁵ Eisenberger, M.⁶

4
- 0027465152
- Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
- (1993) Cancer , vol.71 , pp. 2031-2040
- Schmid, H.-P.¹ McNeal, J.E.² Stamey, T.A.³

5
- 0030965020
- A phase II study of oral Idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time
- (1997) Cancer , vol.79 , pp. 1703-1709
- Schmid, H.-P.¹ Maibach, R.² Bernhard, J.³ Hering, F.⁴ Hanselmann, S.⁵ Gusset, H.⁶

6
- 0026524697
- Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer
- (1992) J Urol , vol.147 , pp. 931-934
- Seidman, A.D.¹ Scher, H.I.² Petrylak, D.³ Dershaw, D.D.⁴ Curley, T.⁵

7
- 0028943667
- Tumor marker doubling time in patients with prostate cancer: Determination of prostate-specific antigen and prostatic acid phosphatase doubling time
- (1995) Eur Urol , vol.27 , pp. 207-212
- Akimoto, S.¹ Masai, M.² Akakura, K.³ Shimazaki, J.⁴

8
- 0029001575
- Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer
- (1995) J Urol , vol.153 , pp. 1860-1865
- Fowler J.E., Jr.¹ Pandey, P.² Seaver, L.E.³ Feliz, T.P.⁴ Braswell, N.T.⁵

9
- 0026522840
- Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
- (1992) JAMA , vol.267 , pp. 2215-2220
- Carter, H.B.¹ Pearson, J.D.² Metter, E.J.³ Brant, L.J.⁴ Chan, D.W.⁵ Andres, R.⁶

10
- 0030339750
- Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values
- (1996) Prostate suppl , vol.7 , pp. 3-16
- Semjonow, A.¹ Brandt, B.² Oberpenning, F.³ Roth, S.⁴ Hertle, L.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.